Melanoma drugs beat chemo

2012-06-04 22:46
Melanoma - benign juvenile example.

Melanoma - benign juvenile example.

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Chicago - Late-stage trials of two experimental skin cancer drugs from GlaxoSmithKline, each designed to block different pathways used by tumour cells, have found the drugs helped patients with fewer side effects than current chemotherapy.

Both drugs, trametinib and dabrafenib, were tested in patients with a mutation in a gene known as BRAF. About half of all melanomas, the deadliest form of skin cancer, have the genetic aberration.

Cancer occurs through genetic changes in cells allowing tumour growth factor receptors which activate various pathways, including a protein known as MEK. It is believed that BRAF-mutated melanomas should be particularly dependent on MEK, which is needed to amplify the cancer's genetic signal.

Roche's Zelboraf, or vemurafenib, is the only BRAF inhibitor currently approved for treating melanoma.

Latest results from a pivotal trial of the Roche drug, presented at a meeting in Chicago of the American Society of Clinical Oncology, found that it improved survival by nearly four months.

But 19% of patients on Zelboraf developed a less-deadly form of skin cancer known as cutaneous squamous cell carcinoma and 10% developed another type of non-malignant lesion. In addition, most patients eventually develop resistance to the drug.

Removing the non-cancerous lesions is not a huge problem, but a drug with fewer such side effects would be appealing, said Dr Kari Kendra, a melanoma specialist at Ohio State University who was not involved in the studies.

"Anytime we don't have to be intrusive is a benefit," she said.

Citi analyst Andrew Baum said dabrafenib was likely to be launched in 2013.

46% reduction

In the trial of Glaxo's trametinib, which is designed to interfere with MEK, patients given the drug lived for a median of 4.8 months before their disease worsened, compared with 1.5 months for patients treated with standard chemotherapy.

The drug was associated with a 46% reduction in the risk of death.

Side effects included skin rash in 7% of patients, eye problems and high blood pressure.

The trial of dabrafenib, a BRAF inhibitor, found that patients on the drug lived for a median of 5.1 months before their disease worsened, compared with 2.7 months for the chemotherapy patients.

Squamous cell carcinomas developed in 6% of the dabrafenib patients, and 3% of them had photosensitivity.

Last month Glaxo announced results from a mid-stage trial showing that patients treated with both trametinib and dabrafenib lived for a median of 7.4 months before their disease got worse. Two percent of patients developed squamous cell cancer and another 2% developed small pre-malignant lesions.

Glaxo is conducting a pivotal trial of the combination treatment and said it plans to file with the regulatory authorities for approval of both drugs as single agent therapies.

About 160 000 new cases of melanoma are diagnosed each year and 48 000 melanoma-related deaths occur worldwide each year.

Read more on:    us  |  research  |  cancer

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

linking and moving

2015-04-22 07:36 publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.